Cell/Gene Tx channel feed

Vi­a­Cyte adds to the war chest in what looks like an IPO-bound ef­fort to bring re­gen­er­a­tive med­i­cine to di­a­betes

4 years ago
Financing

Trail­ing the Big Phar­ma play­ers, a less­er known BC­MA CAR-T can­di­date comes in­to the spot­light

4 years ago
R&D
China

#AS­CO21: SQZ of­fers first clin­i­cal glimpse of un­ortho­dox cell ther­a­py man­u­fac­tur­ing tech — but check­point com­bo is still the way to go

4 years ago
R&D

Or­chard dis­creet­ly ax­es li­cense for 'bub­ble boy' gene ther­a­py, de­spite re­cent pos­i­tive long-term da­ta up­date

4 years ago

FDA steers J&J/Leg­end CAR-T to a quick de­ci­sion as part­ners prep a loom­ing show­down with Bris­tol My­ers, blue­bird

5 years ago
FDA+

Look­ing to build new smart cells, Blue­Rock teams with Tim Lu's Sen­ti Bio in 'sec­ond-or­der' en­gi­neer­ing al­liance

5 years ago
Deals

Re­searchers in biotech, acad­e­mia and Big Phar­ma are of­fer­ing puz­zle pieces to crack CAR-T for sol­id tu­mors. Will they ever snap to­geth­er?

5 years ago
In Focus

Blue­bird’s new gene ther­a­py among three new EMA OKs ahead of FDA

5 years ago
Pharma
FDA+

#AS­CO21: Watch out Bris­tol My­ers, J&J is back at AS­CO with some com­pet­i­tive BC­MA CAR-T da­ta

5 years ago
R&D

Be the spark? Roche’s Spark sues fel­low gene ther­a­py de­vel­op­er blue­bird for ‘usurpa­tion’ of trade­mark

5 years ago

Hours af­ter an­oth­er FDA de­lay, Io­vance CEO re­signs — shares plum­met

5 years ago

CMC holdup de­lays Io­vance fil­ing again — to 2022 — as FDA seeks more as­say da­ta for TIL ther­a­py

5 years ago
FDA+

Months af­ter No­var­tis buy­out, the old Vedere Bio team is back at it with a new pipeline and a fresh $77M

5 years ago
Financing
Startups

Sarep­ta touts clean da­ta for com­mer­cial grade Duchenne gene ther­a­py, clear­ing key hur­dle to PhI­II

5 years ago
R&D

An Ab­b­Vie clin­i­cal vet head­ing ear­ly on­col­o­gy jumps ship to build his own team at NK cell-fo­cused biotech

5 years ago
People

No­bel lau­re­ate David Bal­ti­more throws his weight be­hind I/O start­up look­ing to craft off-the-shelf CAR ther­a­pies

5 years ago
Financing

Dyno's Er­ic Kel­sic fills the tank in his quest for bet­ter AAV with a group of big-name sup­port­ers on board

5 years ago
Financing
AI

Fo­cused on the cell ther­a­py man­u­fac­tur­ing bot­tle­neck, Cel­lares tur­bocharges plans for 'shut­tle' tech

5 years ago
Financing
Manufacturing

Gene ther­a­pies in the knee? With the help of a small herd of hors­es, a new start­up hopes to crack os­teoarthri­tis

5 years ago
Startups

Avro­bio re­tools Fab­ry gene ther­a­py plans af­ter com­pet­ing drug's full ap­proval shuts path­way to an ac­cel­er­at­ed nod

5 years ago

Gene ther­a­py tri­al is de­railed af­ter get­ting hit by the lat­est se­ri­ous ad­verse event in the field — shares crash

5 years ago

Gene ther­a­py deaths push back Astel­las-Au­den­tes' ap­proval by at least two years

5 years ago

Bio­gen re­vers­es course on com­pas­sion­ate use for ALS drug tofersen with plans to open pro­gram in Ju­ly

5 years ago
Pharma

For tai­lored, sin­gle-per­son an­ti­sense oligonu­cleotides, FDA of­fers guid­ance on non­clin­i­cal test­ing

5 years ago
FDA+
First page Previous page 38394041424344 Next page Last page
A service from the Financial Times